Tissue | Dose of PSC 833 | |||
---|---|---|---|---|
Control | 0.1 mg/kg | 0.3 mg/kg | 3 mg/kg | |
Brain | 1.07 ± 0.05 | 1.64 ± 0.04 | 1.34 ± 0.15 | 1.37 ± 0.19 |
Liver | 152 ± 21 | 229 ± 26 | 153 ± 2 | 70.3 ± 10.63-150 |
Intestine | 165 ± 26 | 235 ± 33 | 218 ± 17 | 155 ± 19 |
Kidney | 168 ± 28 | 258 ± 17 | 180 ± 18 | 175 ± 4 |
Adrenal | 203 ± 25 | 277 ± 28 | 159 ± 23 | 125 ± 11 |
Spleen | 242 ± 33 | 344 ± 21 | 245 ± 27 | 179 ± 5 |
Lung | 212 ± 22 | 343 ± 44 | 274 ± 50 | 162 ± 33 |
[3H]VCR was administered i.v. to rats that had received an i.v. injection of PSC 833 (0, 0.1, 0.3, and 3 mg/kg) 30 min before the experiments. At 2 h after administration of [3H]VCR, the tissue-to-plasma concentration was determined. For the plasma, liver, and intestine, HPLC was used to determine the intact [3H]VCR. For other tissues, the total radioactivity was used because we found that more than 80% of the radioactivity was associated with intact [3H]VCR in these tissues. Results are given as the mean ± S.E. of three independent experiments.
↵3-150 P < .05, significantly different from control, using Fisher’s t test.